BOSTON, MASSACHUSETTS, May 29, 2026 — Bioxytran Inc. (OTCQB: BIXT), a biotechnology company developing carbohydrate-based therapeutics and oxygen transport technologies, today highlighted the publication of a newly released scientific book that may provide valuable insights into future evaluation methods for investigational oxygen therapeutics such as BXT-25.
The publication, Physiological Mapping of the Cerebral Cortex in Neuropathology (ISBN: 978-3-032-13018-1), authored independently by internationally recognized physiologist and researcher Dr. Avraham Mayevsky and published by Springer, introduces the concept of Physiological Mapping an integrated methodology designed to monitor tissue metabolism and oxygenation in vivo and in real time.
The work focuses on cerebral physiology and pathophysiology in experimental models involving ischemic stroke, traumatic brain injury, epilepsy, hypoxia, and other neurological disorders where oxygen utilization and tissue viability play critical roles.
A central feature of the book is the application of real-time monitoring technologies, including an FDA-cleared device platform licensed exclusively to Bioxytran. The technology evaluates mitochondrial NADH redox state, a recognized indicator of cellular metabolic activity and oxygen utilization. The research also incorporates simultaneous measurements of cerebral blood flow, tissue oxygen levels, extracellular potassium concentration, DC potential, and electrocorticography (ECoG), creating a comprehensive physiological profile of tissue function during injury and recovery.
Bioxytran believes these methodologies may provide important scientific perspectives for future studies evaluating tissue oxygenation and metabolic responses associated with investigational oxygen therapeutics, including BXT-25.
"Understanding oxygen delivery at both the microvascular and cellular level remains an important challenge in the development of next-generation oxygen therapeutics," said David Platt, PhD, CEO of Bioxytran. "The physiological mapping approaches described by Dr. Mayevsky, who has collaborated with members of Bioxytran's scientific network for decades, may help researchers better understand how therapies such as BXT-25 influence oxygen utilization and tissue metabolism under hypoxic and ischemic conditions."
The publication also examines metabolic oscillations occurring in ischemic brain tissue and explores the role of nitric oxide in conditions including ischemia, hypoxia, hypercapnia, and epilepsy. Additional sections discuss interactions between epilepsy and partial ischemia, responses to hyperoxia and anesthesia, and age-related differences observed in ischemic injury and traumatic brain injury models.
Bioxytran believes that advanced physiological monitoring tools may help expand scientific understanding of tissue hypoxia and support future translational research efforts involving oxygen therapeutics.
BXT-25 is being developed as an investigational oxygen transport therapeutic designed to facilitate oxygen diffusion into tissues experiencing impaired oxygen delivery. The Company continues to evaluate potential applications of BXT-25 in conditions associated with hypoxia, ischemia, and oxygen deprivation.
The publication is expected to be of interest to neurologists, neurosurgeons, anesthesiologists, critical care specialists, and researchers studying cerebral metabolism, tissue oxygenation, and neurological disease.
Bioxytran believes advances in real-time physiological monitoring may contribute to future evaluation methods for oxygen therapeutics by providing deeper insight into tissue oxygen utilization and cellular metabolism under hypoxic conditions.
Dr. Mayevsky's independently authored work highlights methodologies capable of continuously monitoring tissue oxygenation and mitochondrial function, areas that may have relevance for translational research involving investigational oxygen therapeutics such as BXT-25.
The Company believes improved characterization of hypoxic tissue environments may help inform future preclinical research programs, study design considerations, biomarker development, and indication selection strategies.
The physiological mapping approaches described throughout the publication focus on disease models involving ischemia, hypoxia, traumatic brain injury, and epilepsy, reflecting growing scientific interest in disorders characterized by impaired oxygen delivery and utilization.
Bioxytran further believes that monitoring technologies capable of generating real-time metabolic and oxygenation data may support more informed assessment of investigational therapies during future research and development activities.
Dr. Mayevsky has advised and collaborated with members of Bioxytran's scientific network for several decades. The Company believes that ongoing engagement with experienced scientific and academic researchers remains an important component of its development strategy.
BXT-25 is Bioxytran's investigational oxygen transport therapeutic being developed to improve oxygen delivery to hypoxic tissues. The technology utilizes a heme-based oxygen-carrying component linked to a proprietary polysaccharide platform designed to facilitate oxygen diffusion where blood flow may be compromised.
The Company is exploring potential applications of BXT-25 in conditions associated with tissue hypoxia, ischemia, and oxygen deprivation. BXT-25 remains an investigational drug candidate and has not been approved by the U.S. Food and Drug Administration for any indication.
Bioxytran Inc. is a clinical-stage biotechnology company developing carbohydrate-based therapeutics and oxygen transport technologies targeting viral diseases, fibrosis, hypoxia-related disorders, and other significant unmet medical needs. The Company's development programs include galectin antagonists and oxygen therapeutics designed to improve outcomes in conditions associated with inflammation and oxygen deprivation.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential development, evaluation, and future applications of BXT-25 and physiological monitoring technologies. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those described herein. Bioxytran undertakes no obligation to update forward-looking statements except as required by applicable law.
For more information, please visit:
Visit the original announcement:
https://www.otcmarkets.com/stock/BIXT/news/Bioxytran-Highlights-New-Book-on-Real-Time-Monitoring-Tissue-Oxygenation-Relevant-to-Oxygen-Carrier-BXT-25?id=523277
Bioxytran, Inc.
Website: www.bioxytraninc.com
Investor Contact:
David Platt, PhD
Chief Executive Officer
Bioxytran, Inc.
617-484-1199
info@bioxytraninc.com
